Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 2
2009 pubmed 23 citations

The peptide NDP-MSH induces phenotype changes in the heart that resemble ischemic preconditioning.

Catania. Anna A; Lonati. Caterina C; Sordi. Andrea A; Leonardi. Patrizia P; Carlin. Andrea A; Gatti. Stefano S

Key Findings

  • hearts have the melanocortin‑1 receptor (MC1R), allowing NDP‑MSH to act directly on heart tissue.",
  • ,

Practical Outcomes

  • The study shows that melanotan‑I analogues can trigger heart‑protective signaling in animals, but it used a very high IV dose and was done only in rats. There’s no human safety or dosing data, so it’s not ready for self‑experimentation. For now, the main takeaway is that this peptide has potential cardioprotective effects worth watching as more research emerges.

Summary

In rats, a single IV dose of the melanotan‑I analogue NDP‑MSH triggered heart changes that look a lot like the protective effect you get from brief, repeated bouts of low‑oxygen (ischemic pre‑conditioning). The drug boosted certain inflammation‑related signals (IL‑6, STAT3, SOCS3) and a protein called Nur77, which together may help the heart survive damage when blood flow returns after a blockage.

Abstract

alpha-Melanocyte-stimulating hormone (alpha-MSH) is a pro-opiomelanocortin (POMC)-derived peptide that exerts multiple protective effects on host cells. Previous investigations showed that treatment with alpha-MSH or synthetic melanocortin agonists reduces heart damage in reperfusion injury and transplantation. The aim of this preclinical research was to determine whether melanocortin treatment induces preconditioning-like cardioprotection. In particular, the plan was to assess whether melanocortin administration causes phenotype changes similar to those induced by repetitive ischemic events. The idea was conceived because both ischemic preconditioning and melanocortin signaling largely depend on cAMP response element binding protein (CREB) phosphorylation. Rats received single i.v. injections of 750microg/kg of the alpha-MSH analogue Nle(4),DPhe(7)-alpha-MSH (NDP-MSH) or saline and were sacrificed at 0.5, 1, 3, or 5h. Western blot analysis showed that rat hearts expressed melanocortin 1 receptor (MC1R) protein. Treatment with NDP-MSH was associated with early and marked increase in interleukin 6 (IL-6) mRNA. This was followed by signal transducer and activator of transcription 3 (STAT3) phosphorylation and induction of suppressor of cytokine signaling 3 (SOCS3). There were no changes in expression of other cytokines of the IL-6 family. Expression of IL-10, IL-1beta, and TNF-alpha was likewise unaltered. In hearts of rats treated with NDP-MSH there was increased expression of the orphan nuclear receptor Nur77. The data indicate that NDP-MSH induces phenotype changes that closely resemble ischemic preconditioning and likely contribute to its established protection against reperfusion injury. In addition, the increased expression of Nur77 and SOCS3 could be part of a broader anti-inflammatory effect.

Study Information

Provider

pubmed

Year

2009

Date

2009-09-30T00:00:00.000Z

DOI

10.1016/j.peptides.2009.09.030

Citations

23

References

57